key: cord-0882714-pofyp5ao authors: Acharya, Arpan; Pandey, Kabita; Thurman, Michellie; Klug, Elizabeth; Trivedi, Jay; Lorson, Christian L.; Singh, Kamal; Byrareddy, Siddappa N. title: Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors date: 2021-04-02 journal: bioRxiv DOI: 10.1101/2021.04.02.438204 sha: cc26e6a982048ba831326bc27533dc434c9512fe doc_id: 882714 cord_uid: pofyp5ao SARS-CoV-2 infection initiates with the attachment of spike protein to the ACE2 receptor. While vaccines have been developed, no SARS-CoV-2 specific small molecule inhibitors have been approved. Herein, utilizing the crystal structure of the ACE2/Spike receptor binding domain (S-RBD) complex in computer-aided drug design (CADD) approach, we docked ∼8 million compounds within the pockets residing at S-RBD/ACE2 interface. Five best hits depending on the docking score, were selected and tested for their in vitro efficacy to block SARS-CoV-2 replication. Of these, two compounds (MU-UNMC-1 and MU-UNMC-2) blocked SARS-CoV-2 replication at sub-micromolar IC50 in human bronchial epithelial cells (UNCN1T) and Vero cells. Furthermore, MU-UNMC-2 was highly potent in blocking the virus entry by using pseudoviral particles expressing SARS-CoV-2 spike. Finally, we found that MU-UNMC-2 is highly synergistic with remdesivir (RDV), suggesting that minimal amounts are needed when used in combination with RDV, and has the potential to develop as a potential entry inhibitor for COVID-19. Screening library of compounds using computer-aided drug designing approach 114 The flow chart used for screening the library of compounds using a computer-aided drug 115 design approach is depicted in Fig. 1A . Out of the 8 million compounds screened, we 116 selected five compounds to test their efficacy in the cell-based assays. The IUPAC name, 117 molecular structure, and glide score of the compounds are described in Table S1 . The F. MU-UNMC-1 and MU-UNMC-2 anchored with a Glide score of -9.8 and -11.6. Whereas the docking score of MU-UNMC-6, MU-UNMC-7, and MU-UNMC-8 were -7.6, -7.2, and -6.4, respectively. Compound MU-UNMC-1 was docked in a pocket formed by 122 spike residues R403, E406, Y453, Y505, and ACE2 residues H34, E37 (Fig. 1B) . Compound MU-UNMC-2 is docked in a pocket formed by spike residues R403, E405, 124 E406, Y453, Y505, and ACE2 residues H34, E37, and D38 (Fig. 1C) . Compounds MU- Vero-STAT1 knockout cells was 6.21 µM for MU-UNMC-1 ( Fig. 2A) , 7.13 µM for MU-138 UNMC-2 (Fig. 2B) , 37.18 µM for MU-UNMC-6 ( Fig. 2C) , 11.43 µM for MU-UNMC-7 (Fig. 139 2D) and 8.11 µM for MU-UNMC-8 (Fig. 2E) respectively. We found that in-silico MU-UNMC-1 docked in two binding modes in the interface of spike 179 and ACE-2 (Fig. S2) . In the second binding mode, MU-UNMC-1 interacts with only a few 180 9 residues. The two binding modes of the compound may be unstable at the interface of 181 RBD and ACE2, leading to its low efficacy in pseudotyped assays. Chemical properties of MU-UNMC-2 183 We used the SwissADME web portal to compute the biophysical properties of all the Our strategy that combines in silico drug screening followed by in vitro testing in the cell- based system has a significant advantage over the classical drug-discovery approaches. It substantially reduces the resource and expenses for initial screening of drug-like 305 compounds, increases the probability of selecting the best lead compounds with desired 306 therapeutic profile with fewer trials. Our strategy also shortens the time between the lead 307 identification-to optimization, preclinical test, to translational application to clinical trials. While we have not optimized the lead compound, we are in the process of doing so, and 309 the results will be presented elsewhere. However, initial theoretical estimation of the 310 ADME profile suggests that the compound MU-UNMC-2 has a favorable physicochemical 311 profile and can be quickly taken into pre-clinical trials. Once the ADME profile is confirmed A novel coronavirus outbreak of global 580 health concern Severe acute respiratory syndrome 582 coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies The proximal origin 585 of SARS-CoV-2 Structures and 587 distributions of SARS-CoV-2 spike proteins on intact virions SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets Antigenicity of the SARS-CoV-2 Spike Glycoprotein SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 597 Proteolytic 599 Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases 600 beyond Furin Targeting the Endocytic Pathway and Autophagy Process as 602 a Novel Therapeutic Strategy in COVID-19 Development of vaccines and antivirals for combating viral 604 pandemics Covid-19 Commission of Accademia Nazionale dei Lincei COVID-19 vaccines: where we stand and challenges ahead Allergic Reactions Including Anaphylaxis After Receipt 609 of the First Dose of Moderna COVID-19 Vaccine -United States Vaccine efficacy probable against COVID-19 variants SARS-CoV-2 Vaccines: Much 614 Repurposing drugs for the management 616 of COVID-19 Drug 618 repurposing approach to fight COVID-19 COVID-19) treatment: a review of evidence Remdesivir for the Treatment of Covid-19 -Final Report Repurposed Antiviral Drugs for Covid-19 -Interim WHO 627 Solidarity Trial Results Structure of the SARS-CoV-2 629 spike receptor-binding domain bound to the ACE2 receptor Spike proteins of novel MERS-632 coronavirus isolates from North-and West-African dromedary camels mediate robust viral 633 entry into human target cells Quantitative analysis of dose-effect relationships: the 635 combined effects of multiple drugs or enzyme inhibitors Peptide and peptide-based inhibitors of SARS-CoV-2 entry Human 641 ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection Stapled 644 ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent 645 virus internalization Evidence supporting 647 the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) 648 therapeutics A human 650 monoclonal antibody blocking SARS-CoV-2 infection Human monoclonal antibodies 652 block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 653 receptor Therapeutic antibodies and fusion inhibitors targeting the 655 spike protein of SARS-CoV-2 Inhibitors of SARS-CoV-2 657 Entry: Current and Future Opportunities Gurevich EV, Gurevich VV. Therapeutic potential of small molecules and 662 engineered proteins What are the drugs of the future? Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The 670 Novel 672 peptide inhibitors of angiotensin-converting enzyme 2 Computational Design of ACE2-Based Peptide Inhibitors of SARS-675 A 677 novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts 678 angiotensin I to angiotensin 1-9 Angiotensin-converting 680 enzyme 2 protects from severe acute lung failure Identification and 682 Tracking of Antiviral Drug Combinations Drug Repurposing Approaches to Combating 684 Viral Infections Theoretical basis, experimental design, and computerized simulation of 686 synergism and antagonism in drug combination studies The evolution of three decades of antiretroviral 689 therapy: challenges, triumphs and the promise of the future Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19 Triple combination 695 of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted 696 32 to hospital with COVID-19: an open-label, randomised, phase 2 trial Safety profile of the antiviral drug remdesivir: An 699 update Animal models 701 for SARS-CoV-2 research: A comprehensive literature review Market design to 704 accelerate COVID-19 vaccine supply design/computer-aided manufacture techniques for removable denture fabrication SwissADME: a free web tool to evaluate 709 pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules iLOGP: a simple, robust, and efficient description 712 of n-octanol/water partition coefficient for drug design using the GB/SA approach A BOILED-Egg To Predict Gastrointestinal Absorption and Brain 715 Penetration of Small Molecules Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike 718 Protein for Neutralization Assays Two Detailed Plaque Assay 720 Protocols for the Quantification of Infectious SARS-CoV-2 Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-alpha/mTOR/BRD4 724 inhibitor Drug combination studies and their synergy quantification using the 726 SynergyFinder 2.0: visual analytics of multi-drug 728 combination synergies